Michael P. Johnson

3.3k total citations
52 papers, 2.6k citations indexed

About

Michael P. Johnson is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Clinical Psychology. According to data from OpenAlex, Michael P. Johnson has authored 52 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Cellular and Molecular Neuroscience, 20 papers in Molecular Biology and 10 papers in Clinical Psychology. Recurrent topics in Michael P. Johnson's work include Neuroscience and Neuropharmacology Research (25 papers), Neurotransmitter Receptor Influence on Behavior (14 papers) and Psychedelics and Drug Studies (10 papers). Michael P. Johnson is often cited by papers focused on Neuroscience and Neuropharmacology Research (25 papers), Neurotransmitter Receptor Influence on Behavior (14 papers) and Psychedelics and Drug Studies (10 papers). Michael P. Johnson collaborates with scholars based in United States, Canada and United Kingdom. Michael P. Johnson's co-authors include David E. Nichols, Darryle D. Schoepp, Andrew J. Hoffman, James A. Monn, A. Linden, Chad J. Swanson, Mark G. Bures, Eric S. Nisenbaum, Robert Oberlender and G. Erik Jagdmann and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Nature Reviews Drug Discovery.

In The Last Decade

Michael P. Johnson

51 papers receiving 2.6k citations

Peers

Countries citing papers authored by Michael P. Johnson

Since Specialization

Citations

This map shows the geographic impact of Michael P. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael P. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael P. Johnson more than expected).

Fields of papers citing papers by Michael P. Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael P. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael P. Johnson. The network helps show where Michael P. Johnson may publish in the future.

Co-authorship network of co-authors of Michael P. Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Michael P. Johnson. A scholar is included among the top collaborators of Michael P. Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael P. Johnson. Michael P. Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	In Vitro Pharmacological Characterization and In Vivo Validation of LSN3172176 a Novel M1 Selective Muscarinic Receptor Agonist Tracer Molecule for Positron Emission Tomography 2018 ·Journal of Pharmacology and Experimental Therapeutics ·Adrian J. Mogg, Thomas E. Eessalu, Megan Johnson, Rebecca A. Wright, Helen Sanger, (unknown), Michael Crabtree, (unknown), (unknown), Douglas A. Schober, Donald R. Gehlert, Cynthia D. Jesudason, Paul Goldsmith, Michael P. Johnson, Christian C. Felder, Vanessa Barth, Lisa M. Broad	8
2	Discovery of dual positive allosteric modulators (PAMs) of the metabotropic glutamate 2 receptor and CysLT1 antagonists for treating migraine headache 2016 ·Bioorganic & Medicinal Chemistry Letters ·María‐Jesús Blanco, (unknown), (unknown), Albert Khilevich, Guillermo S. Cortez, (unknown), Thomas D. Aicher, (unknown), (unknown), Tony P. Tang, Kirk W. Johnson, (unknown), Mark Muhlhauser, Steven Swanson, John T. Catlow, Renee Emkey, Michael P. Johnson, Jeffrey M. Schkeryantz	5
3	Paradoxical effects of the cannabinoid CB2 receptor agonist GW405833 on rat osteoarthritic knee joint pain 2010 ·Osteoarthritis and Cartilage ·Niklas Schuelert, (unknown), Adrian J. Mogg, (unknown), Deena L. Hepburn, Eric S. Nisenbaum, Michael P. Johnson, Jason J. McDougall	67
4	Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis 2010 ·Pain ·Niklas Schuelert, Michael P. Johnson, J.L. Oskins, (unknown), M.G. Chambers, Jason J. McDougall	65
5	An Animal Model of Emotional Blunting in Schizophrenia 2007 ·PLoS ONE ·Charmaine Y. Pietersen, Fokko J. Bosker, Janine Doorduin, Minke E. Jongsma, Folkert Postema, Joseph V. Haas, Michael P. Johnson, Tineke Koch, Tony Vladusich, Johan A. den Boer	24
6	Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s) 2005 ·Psychopharmacology ·Michael P. Johnson, David A. Barda, Thomas C. Britton, Renee Emkey, William J. Hornback, G. Erik Jagdmann, David L. McKinzie, Eric S. Nisenbaum, Joseph P. Tizzano, Darryle D. Schoepp	126
7	SAR study of a subtype selective allosteric potentiator of metabotropic glutamate 2 receptor, N-(4-phenoxyphenyl)-N-(3-pyridinylmethyl)ethanesulfonamide 2004 ·Bioorganic & Medicinal Chemistry Letters ·David A. Barda, Zhaoqing Wang, Thomas C. Britton, Steven S. Henry, G. Erik Jagdmann, (unknown), Michael P. Johnson, Sherri L. Andis, Darryle D. Schoepp	40
8	Group II Metabotropic Glutamate Receptor Modulation of DOI-induced c-fos mRNA and Excitatory Responses in the Cerebral Cortex 2003 ·Neuropsychopharmacology ·Yan Zhai, Carolyn George, Jin Zhai, Eric S. Nisenbaum, Michael P. Johnson, Laura K. Nisenbaum	60
9	Changes in Rat Serum Corticosterone After Treatment with Metabotropic Glutamate Receptor Agonists or Antagonists 2001 ·Journal of Neuroendocrinology ·Michael P. Johnson, (unknown), (unknown)	39
10	Blockade of pilocarpine-induced cerebellar phosphoinositide hydrolysis with metabotropic glutamate antagonists: evidence for an indirect control of granule cell glutamate release by muscarinic agonists 2000 ·Neuroscience Letters ·Michael P. Johnson, (unknown), (unknown)	5
11	Phosphoinositide hydrolysis in vivo with group I metabotropic glutamate receptor agonists 1999 ·Brain Research ·Michael P. Johnson, (unknown), (unknown)	21
12	Temporal dependent neuroprotection with propentofylline (HWA 285) in a temporary focal ischemia model 1998 ·European Journal of Pharmacology ·Michael P. Johnson, (unknown), Paula A. Chmielewski	12
13	MDL 101,002, a free radical spin trap, is efficacious in permanent and transient focal ischemia models 1998 ·Life Sciences ·Michael P. Johnson, (unknown), Nelson L. Velayo, Carrie G. Markgraf, Paula A. Chmielewski, James Ficorilli, Hsien C. Cheng, Craig E. Thomas	11
14	Stereoselective LSD-like activity in d-lysergic acid amides of R- and S-2-aminobutane 1992 ·Journal of Medicinal Chemistry ·Robert Oberlender, (unknown), Michael P. Johnson, Xuemei Huang, David E. Nichols	16
15	Combined administration of a non-neurotoxic 3,4-methylenedioxymethamphetamine analogue with amphetamine produces serotonin neurotoxicity in rats 1991 ·Neuropharmacology ·Michael P. Johnson, David E. Nichols	22
16	2,3-Dihydrobenzofuran analogs of hallucinogenic phenethylamines 1991 ·Journal of Medicinal Chemistry ·David E. Nichols, Scott E. Snyder, Robert Oberlender, Michael P. Johnson, Xuemei Huang	41
17	Reduction in brain serotonin markers by α-ethyltryptamine (Monase) 1991 ·European Journal of Pharmacology ·Huang Xuemei, Michael P. Johnson, D. E. NICHOLS	13
18	Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: similarities to 3,4-(methylenedioxy)methamphetamine (MDMA) 1991 ·Journal of Medicinal Chemistry ·Michael P. Johnson, (unknown), Robert Oberlender, David E. Nichols	48
19	Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic 3,4-methylenedioxymethamphetamine (MDMA) analogue 1991 ·Pharmacology Biochemistry and Behavior ·Michael P. Johnson, Huang Xuemei, David E. Nichols	31
20	Studies of dioxole ring substituted 3,4-methylenedioxyamphetamine (MDA) analogues 1989 ·Pharmacology Biochemistry and Behavior ·David E. Nichols, Robert Oberlender, Kevin D. Burris, Andrew J. Hoffman, Michael P. Johnson	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact